Seres Therapeutics Inc. (MCRB) Sees Large Volume Increase
Seres Therapeutics Inc. (NASDAQ:MCRB) saw strong trading volume on Friday . 30,051,027 shares traded hands during mid-day trading, an increase of 1,595% from the previous session’s volume of 1,773,120 shares.The stock last traded at $10.98 and had previously closed at $35.77.
A number of equities research analysts have commented on the stock. Canaccord Genuity reissued a “buy” rating on shares of Seres Therapeutics in a research report on Sunday, May 29th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research report on Friday. HC Wainwright assumed coverage on shares of Seres Therapeutics in a research report on Friday. They issued a “buy” rating and a $50.00 price objective on the stock. FBR & Co reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday, May 2nd. Finally, Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 18th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $43.14.
The company’s 50-day moving average price is $30.79 and its 200-day moving average price is $28.09. The company’s market cap is $432.34 million.
Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Monday, May 16th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.02. The company had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $1.25 million. On average, analysts predict that Seres Therapeutics Inc. will post ($1.87) earnings per share for the current fiscal year.
In other Seres Therapeutics news, insider Michele Trucksis sold 4,156 shares of Seres Therapeutics stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $35.18, for a total transaction of $146,208.08. Following the transaction, the insider now directly owns 4,156 shares of the company’s stock, valued at $146,208.08. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider John G. Aunins sold 9,390 shares of Seres Therapeutics stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $34.18, for a total transaction of $320,950.20. Following the transaction, the insider now directly owns 220,155 shares in the company, valued at $7,524,897.90. The disclosure for this sale can be found here.
Other hedge funds and institutional investors have made changes to their positions in the company. ProShare Advisors LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter worth $1,146,000. Morgan Stanley boosted its position in shares of Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock worth $1,185,000 after buying an additional 23,381 shares during the period. Jennison Associates LLC boosted its position in shares of Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock worth $13,999,000 after buying an additional 7,259 shares during the period. Finally, BlackRock Advisors LLC boosted its position in shares of Seres Therapeutics by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 340,871 shares of the company’s stock worth $11,962,000 after buying an additional 2,443 shares during the period.
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.